Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma - a retrospective single-institute study

Sep 21, 2026

Uploaded by Eden

This retrospective single-institute study evaluates whether abnormal p53 expression predicts outcomes in stage I, low-grade (grade 1 or 2) endometrial endometrioid carcinoma. Women treated at MacKay Memorial Hospital between January 2019 and December 2022 were included, and immunohistochemistry was used to detect abnormal p53. Among 115 patients, 26 showed pathologically confirmed abnormal p53. Recurrence, mortality, and progression-free survival were significantly worse in the p53 abnormal group, with an overall survival trend toward poorer outcomes. Results support abnormal p53 as an indicator of poor prognosis and suggest consideration of more intensive adjuvant therapy.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Abstract

Objective

Methods

Results

Conclusion

Synopsis and Introduction

J Gynecol Oncol. 2024 Nov;35(6):e78 [https://doi.org/10.3802/jgo.2024.35.e78](https://doi.org/10.3802/jgo.2024.35.e78)[ ](https://doi.org/10.3802/jgo.2024.35.e78)pISSN 2005-0380·eISSN 2005-0399 Original Article Received: Nov 6, 2023 Revised: Feb 4, 2024 Accepted: Feb 25, 2024 Published online: Mar 22, 2024 Correspondence to Jen-Ruei Chen Department of Obstetrics & Gynecology, MacKay Memorial Hospital, No. 92, Sec. 2, Chung-Sang North Rd, Chung-Sang Dist. Taipei 10464, Taiwan, Republic of China. Email: [justyray@mmh.org.tw](justyray@mmh.org.tw)[ ](justyray@mmh.org.tw)[cremaster4471@gmail.com](cremaster4471@gmail.com) © 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ORCID iDs Yu-Wei Chang [https://orcid.org/0009-0008-1587-1075](https://orcid.org/0009-0008-1587-1075)[ ](https://orcid.org/0009-0008-1587-1075)Hsiao-Li Kuo [https://orcid.org/0009-0004-6336-807X](https://orcid.org/0009-0004-6336-807X)[ ](https://orcid.org/0009-0004-6336-807X)Tzu-Chien Chen [https://orcid.org/0000-0001-6338-7079](https://orcid.org/0000-0001-6338-7079)[ ](https://orcid.org/0000-0001-6338-7079)Jessica Chen [https://orcid.org/0009-0001-4999-2704](https://orcid.org/0009-0001-4999-2704)[ ](https://orcid.org/0009-0001-4999-2704)Ling Lim [https://orcid.org/0000-0001-7555-6394](https://orcid.org/0000-0001-7555-6394)[ ](https://orcid.org/0000-0001-7555-6394)[Kung-LiahngWang](Kung-LiahngWang) [https://orcid.org/0000-0002-9439-0622](https://orcid.org/0000-0002-9439-0622)[ ](https://orcid.org/0000-0002-9439-0622)Jen-Ruei Chen [https://orcid.org/0000-0001-8475-8705](https://orcid.org/0000-0001-8475-8705) Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study Yu-Wei Chang ,1 Hsiao-Li Kuo ,2 Tzu-Chien Chen ,3 Jessica Chen ,4 Ling Lim ,4 Kung-Liahng Wang ,1,5 Jen-Ruei Chen 1,5,6 1Department of Obstetrics & Gynecology, MacKay Memorial Hospital, Taipei, Taiwan 2Department of Nursing, MacKay Memorial Hospital, Taipei, Taiwan 3Department of Obstetrics & Gynecology, MacKay Memorial Hospital, Hsinchu Branch, Hsinchu, Taiwan 4Department of Obstetrics & Gynecology, MacKay Memorial Hospital, Tamsui Branch, New Taipei City, Taiwan 5Department of General Education, MacKay Junior College of Medicine, Nursing and Management, New Taipei City, Taiwan 6Department of Medicine, MacKay Medical College, New Taipei City, Taiwan ABSTRACT Objective: The Cancer Genome Atlas study revealed an association between copy-number high (p53 abnormal) genetic mutation and poor prognosis in endometrial cancer in 2013. This retrospective study investigated outcomes in patients with abnormal p53 expression and stage I, low-grade endometrial endometrioid carcinoma (EEC) . Methods: We enrolled women with stage I, grade 1 or 2 EEC who received comprehensive staging and adjuvant therapy between January 2019 and December 2022 at MacKay Memorial Hospital, Taipei, Taiwan. Pathologists interpreted immunohistochemistry stains of cancerous tissues to detect p53 mutation. We compared recurrence, survival, progressionfree survival, and overall survival between p53 abnormal and p53 normal groups. Results: Of the 115 patients included, 26 had pathologically confirmed abnormal p53 expression. Of these 26 patients, five (19.2%) experienced recurrence, and two died due to disease progression. By contrast, no patients in the normal p53 group experienced disease recurrence or died due to disease progression. Significant intergrou

FAQs

What patient population was analyzed in the study?

Women with stage I, grade 1 or 2 endometrial endometrioid carcinoma who received comprehensive staging and adjuvant therapy between January 2019 and December 2022 were included.

How was p53 abnormality determined?

Pathologists interpreted immunohistochemistry staining of cancerous tissues to detect p53 abnormality.

What outcomes differed between p53 abnormal and p53 normal groups?

The p53 abnormal group showed significantly higher rates of recurrent disease status and mortality, along with worse progression-free survival; overall survival also showed a poorer trend.

Sep 21, 2026

Uploaded by Eden